📊 GRDN Key Takeaways
Is Guardian Pharmacy Services, Inc. (GRDN) a Good Investment?
Guardian Pharmacy Services demonstrates fundamental deterioration despite 17.9% revenue growth, with net income growth of only 0.5% YoY indicating margin compression. Most critically, the company generated negative free cash flow of -$7.4M despite $13.3M net income, revealing the business is not converting earnings to cash and is unsustainable at current capital requirements.
Guardian shows strong top-line growth and high returns on capital on a debt-free, liquid balance sheet, producing free cash flow above net income thanks to low capex and solid operations. Net income growth lags revenue, indicating margin pressure; sustained cost discipline and mix improvements would unlock operating leverage while preserving cash generation.
Why Buy Guardian Pharmacy Services, Inc. Stock? GRDN Key Strengths
- Strong revenue growth of 17.9% YoY demonstrates market expansion
- Zero long-term debt provides financial flexibility and eliminates interest burden
- Adequate liquidity with current ratio of 1.46x and $64.9M cash reserves
- Debt-free with solid liquidity and $65.6M cash
- High ROE (22.6%) and ROA (11.9%)
- Robust cash generation (6.0% FCF margin; OCF > NI)
GRDN Stock Risks: Guardian Pharmacy Services, Inc. Investment Risks
- Negative free cash flow of -$7.4M despite profitability signals unsustainable business model with cash burn
- Net income growth of 0.5% YoY versus 17.9% revenue growth indicates significant margin compression and deteriorating profitability
- Critically low profitability metrics (3.9% net margin, 5.3% operating margin) with weak capital returns (ROE 5.7%, ROA 3.1%) suggest structural challenges in the pharmacy retail sector
- Margin pressure: net income growth (0.5% YoY) trails revenue growth (17.9%)
- OCF buoyed by working-capital timing may normalize
- Thin net margin (3.4%) leaves limited buffer for cost shocks
Key Metrics to Watch
- Free Cash Flow trajectory - must turn positive to validate business sustainability
- Operating Margin trend - currently at 5.3%, requires improvement to justify scale of operations
- Capital Expenditure as % of revenue - capex at 4.0% of revenue exceeded operating cash flow, need to validate ROI on capital deployment
- Operating margin
- OCF/Net income conversion
Guardian Pharmacy Services, Inc. (GRDN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Guardian Pharmacy Services, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
GRDN Profit Margin, ROE & Profitability Analysis
GRDN vs Consumer Sector: How Guardian Pharmacy Services, Inc. Compares
How Guardian Pharmacy Services, Inc. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Guardian Pharmacy Services, Inc. Stock Overvalued? GRDN Valuation Analysis 2026
Based on fundamental analysis, Guardian Pharmacy Services, Inc. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Guardian Pharmacy Services, Inc. Balance Sheet: GRDN Debt, Cash & Liquidity
GRDN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Guardian Pharmacy Services, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
GRDN Revenue Growth, EPS Growth & YoY Performance
GRDN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $329.3M | $9.4M | N/A |
| Q3 2025 | $314.4M | $9.0M | N/A |
| Q2 2025 | $300.0M | N/A | N/A |
| Q1 2025 | $275.4M | $9.4M | N/A |
| Q3 2024 | $262.7M | -$122.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Guardian Pharmacy Services, Inc. Dividends, Buybacks & Capital Allocation
GRDN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Guardian Pharmacy Services, Inc. (CIK: 0001802255)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GRDN
What is the AI rating for GRDN?
Guardian Pharmacy Services, Inc. (GRDN) has a Combined AI Rating of HOLD from Claude (SELL) and ChatGPT (BUY) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GRDN's key strengths?
Claude: Strong revenue growth of 17.9% YoY demonstrates market expansion. Zero long-term debt provides financial flexibility and eliminates interest burden. ChatGPT: Debt-free with solid liquidity and $65.6M cash. High ROE (22.6%) and ROA (11.9%).
What are the risks of investing in GRDN?
Claude: Negative free cash flow of -$7.4M despite profitability signals unsustainable business model with cash burn. Net income growth of 0.5% YoY versus 17.9% revenue growth indicates significant margin compression and deteriorating profitability. ChatGPT: Margin pressure: net income growth (0.5% YoY) trails revenue growth (17.9%). OCF buoyed by working-capital timing may normalize.
What is GRDN's revenue and growth?
Guardian Pharmacy Services, Inc. reported revenue of $336.6M.
Does GRDN pay dividends?
Guardian Pharmacy Services, Inc. does not currently pay dividends.
Where can I find GRDN SEC filings?
Official SEC filings for Guardian Pharmacy Services, Inc. (CIK: 0001802255) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GRDN's EPS?
Guardian Pharmacy Services, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GRDN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Guardian Pharmacy Services, Inc. has a HOLD rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GRDN stock overvalued or undervalued?
Valuation metrics for GRDN: ROE of 5.7% (sector avg: 18%), net margin of 3.9% (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy GRDN stock in 2026?
Our dual AI analysis gives Guardian Pharmacy Services, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GRDN's free cash flow?
Guardian Pharmacy Services, Inc.'s operating cash flow is $6.1M, with capital expenditures of $13.4M. FCF margin is -2.2%.
How does GRDN compare to other Consumer stocks?
Vs Consumer sector averages: Net margin 3.9% (avg: 8%), ROE 5.7% (avg: 18%), current ratio 1.46 (avg: 1.5).